Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits

eLife

Volumn 4, Issue September, 2015, Pages

  Acosta Alvear, Diego ^a,b   Cho, Min Y ^a,b   Wild, Thomas ^c   Buchholz, Tonia J ^d   Lerner, Alana G ^d   Simakova, Olga ^e   Hahn, Jamie ^e   Korde, Neha ^f,g   Landgren, Ola ^f,g   Maric, Irina ^e   Choudhary, Chunaram ^c   Walter, Peter ^a,b   Weissman, Jonathan S ^a,b   Kampmann, Martin ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of Copenhagen   (Denmark)

^d ONYX PHARMACEUTICALS   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; LENALIDOMIDE; LENTIVIRUS VECTOR; RETROVIRUS VECTOR; SHORT HAIRPIN RNA; ANTINEOPLASTIC AGENT; OLIGOPEPTIDE; PROTEASOME; PROTEASOME INHIBITOR;

19S PROTEASOMAL SUBUNIT; ARTICLE; BIOINFORMATICS; CELL GROWTH; CELL VIABILITY; CLINICAL TRIAL; DESENSITIZATION; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; IMMUNE RESPONSE; IMMUNOBLOTTING; MASS SPECTROMETRY; MULTIPLE MYELOMA; NEXT GENERATION SEQUENCING; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN HOMEOSTASIS; PROTEIN SUBUNIT; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VALIDATION PROCESS; VIRAL GENE DELIVERY SYSTEM; DRUG RESISTANCE; ENZYMOLOGY; HUMAN; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIPLE MYELOMA; OLIGOPEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS;

EID: 84945910268     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.08153     Document Type: Article

References (52)

1. Balch WE, Morimoto RI, Dillin A, Kelly JW. 2008. Adapting proteostasis for disease intervention. Science 319:916-919. doi: 10.1126/science.1141448.
2. Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, Cerruti F, Orsi A, Pasqualetto E, Mezghrani A, Calbi V, Palladini G, Giuliani N, Anderson KC, Sitia R, Cenci S. 2009. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 113:3040-3049. doi: 10.1182/ blood-2008-08-172734.
3. Braunstein MJ, Scott SS, Scott CM, Behrman S, Walter P, Wipf P, Coplan JD, Chrico W, Joseph D, Brodsky JL, Batuman O. 2011. Antimyeloma effects of the heat shock protein 70 molecular chaperone inhibitor MAL3-101. Journal of Oncology 2011:232037. doi: 10.1155/2011/232037.
4. Breslow DK, Cameron DM, Collins SR, Schuldiner M, Stewart-Ornstein J, Newman HW, Braun S, Madhani HD, Krogan NJ, Weissman JS. 2008. A comprehensive strategy enabling high-resolution functional analysis of the yeast genome. Nature Methods 5:711-718. doi: 10.1038/nmeth.1234.
5. Buac D, Shen M, Schmitt S, Kona FR, Deshmukh R, Zhang Z, Neslund-Dudas C, Mitra B, Dou QP. 2013. From bortezomib to other inhibitors of the proteasome and beyond. Current Pharmaceutical Design 19:4025-4038. doi: 10.2174/1381612811319220012.
6. Cenci S, Oliva L, Cerruti F, Milan E, Bianchi G, Raule M, Mezghrani A, Pasqualetto E, Sitia R, Cascio P. 2012. Pivotal Advance: protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors. Journal of Leukocyte Biology 92:921-931. doi: 10.1189/jlb.1011497.
7. Chen S, Blank JL, Peters T, Liu XJ, Rappoli DM, Pickard MD, Menon S, Yu J, Driscoll DL, Lingaraj T, Burkhardt AL, Chen W, Garcia K, Sappal DS, Gray J, Hales P, Leroy PJ, Ringeling J, Rabino C, Spelman JJ, Morgenstern JP, Lightcap ES. 2010. Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Research 70:4318-4326. doi: 10.1158/0008-5472.CAN- 09-4428.
8. Cox J, Mann M. 2008. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nature Biotechnology 26:1367-1372. doi: 10.1038/nbt.1511.
9. Demchenko YN, Kuehl WM. 2010. A critical role for the NFkB pathway in multiple myeloma. Oncotarget 1:59-68. doi: 10.18632/oncotarget.109.
10. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV, International Myeloma Working Group. 2006. International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473. doi: 10.1038/sj.leu.2404284.
11. Elias JE, Gygi SP. 2007. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nature Methods 4:207-214. doi: 10.1038/nmeth1019.
12. Giaever G, Shoemaker DD, Jones TW, Liang H, Winzeler EA, Astromoff A, Davis RW. 1999. Genomic profiling of drug sensitivities via induced haploinsufficiency. Nature Genetics 21:278-283. doi: 10.1038/6791.
13. Gorbea C, Goellner GM, Teter K, Holmes RK, Rechsteiner M. 2004. Characterization of mammalian Ecm29, a 26 S proteasome-associated protein that localizes to the nucleus and membrane vesicles. The Journal of Biological Chemistry 279:54849-54861. doi: 10.1074/jbc.M410444200.
14. Huang DW, Sherman BT, Lempicki RA. 2009a. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols 4:44-57. doi: 10.1038/nprot.2008.211.
15. Huang DW, Sherman BT, Lempicki RA. 2009b. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Research 37:1-13. doi: 10.1093/nar/gkn923.
16. Huber EM, Heinemeyer W, Groll M. 2015. Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914. Structure 23:407-417. doi: 10.1016/j.str.2014.11.019.
17. Ishii T, Seike T, Nakashima T, Juliger S, Maharaj L, Soga S, Akinaga S, Cavenagh J, Joel S, Shiotsu Y. 2012. Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J 2:e68. doi: 10.1038/bcj.2012.13.
18. Kampmann M, Bassik MC, Weissman JS. 2013. Integrated platform for genome-wide screening and construction of high-density genetic interaction maps in mammalian cells. Proceedings of the National Academy of Sciences of USA 110:E2317-E2326. doi: 10.1073/pnas.1307002110.
19. KampmannM, Bassik MC, Weissman JS. 2014. Functional genomics platform for pooled screening and generation of mammalian genetic interaction maps. Nature Protocols 9:1825-1847. doi: 10.1038/nprot.2014.103.
20. Kampmann M, Horlbeck MA, Chen Y, Tsai JC, Bassik MC, Gilbert LA, Villalta JE, Kwon SC, Chang H, Kim VN, Weissman JS. 2015. Next-generation libraries for robust RNA interference-based genome-wide screens. Proceedings of the National Academy of Sciences of USA 112:E3384-E3391. doi: 10.1073/pnas.1508821112.
21. Kawaguchi T, Miyazawa K, Moriya S, Ohtomo T, Che XF, Naito M, Itoh M, Tomoda A. 2011. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress. International Journal of Oncology 38:643-654. doi: 10.3892/ijo.2010.882.
22. Komatsu S, Moriya S, Che XF, Yokoyama T, Kohno N, Miyazawa K. 2013. Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells. Biochemical and Biophysical Research Communications 437:41-47. doi: 10.1016/j.bbrc.2013.06.032.
23. Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Mailankody S, Wu P, Morrison C, Costello R, Zhang Y, Burton D, Mulquin M, Zuchlinski D, Lamping L, Carpenter A, Wall Y, Carter G, Cunningham SC, Gounden V, Sissung TM, Peer C, Maric I, Calvo KR, Braylan R, Yuan C, Stetler- Stevenson M, Arthur DC, Kong KA, Weng L, Faham M, Lindenberg L, Kurdziel K, Choyke P, Steinberg SM, Figg W, Landgren O. 2015. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncology 1:746-754. doi: 10.1001/ jamaoncol.2015.2010.
24. Liu C-W, Jacobson AD. 2013. Functions of the 19S complex in proteasomal degradation. Trends in Biochemical Sciences 38:103-110. doi: 10.1016/j.tibs.2012.11.009.
25. Mateos MV, Hernández MT, Giraldo P, de la Rubia J, de Arriba F, López Corral L, Rosiñol L, Paiva B, Palomera L, Bargay J, Oriol A, Prosper F, López J, Olavarría E, Quintana N, García JL, Bladé J, Lahuerta JJ, San Miguel JF. 2013. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. The New England Journal of Medicine 369:438-447. doi: 10.1056/NEJMoa1300439.
26. Matheny CJ, Wei MC, Bassik MC, Donnelly AJ, Kampmann M, Iwasaki M, Piloto O, Solow-Cordero DE, Bouley DM, Rau R, Brown P, McManus MT, Weissman JS, Cleary ML. 2013. Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens. Chemistry & Biology 20:1352-1363. doi: 10.1016/j.chembiol.2013.09.014.
27. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, Hahn S, Schreiber S, Wilhelm S, Herrmann M, Jäck HM, Voll RE. 2007. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Research 67:1783-1792. doi: 10.1158/0008-5472.CAN-06-2258.
28. Mishima Y, Santo L, Eda H, Cirstea D, Nemani N, Yee AJ, O'Donnell E, Selig MK, Quayle SN, Arastu-Kapur S, Kirk C, Boise LH, Jones SS, Raje N. 2015. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death. British Journal of Haematology 169:423-434. doi: 10.1111/bjh.13315.
29. Moriya S, Che XF, Komatsu S, Abe A, Kawaguchi T, Gotoh A, Inazu M, Tomoda A, Miyazawa K. 2013. Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stressmediated CHOP induction in myeloma cells. International Journal of Oncology 42:1541-1550. doi: 10.3892/ ijo.2013.1870.
30. Morris LL, Hartman IZ, Jun D-J, Seemann J, DeBose-Boyd RA. 2014. Sequential actions of the AAA-ATPase valosin-containing protein (VCP)/p97 and the proteasome 19 S regulatory particle in sterol-accelerated, endoplasmic reticulum (ER)-associated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. The Journal of Biological Chemistry 289:19053-19066. doi: 10.1074/jbc.M114.576652.
31. N'Diaye E-N, Kajihara KK, Hsieh I, Morisaki H, Debnath J, Brown EJ. 2009. PLIC proteins or ubiquilins regulate autophagy-dependent cell survival during nutrient starvation. EMBO Reports 10:173-179. doi: 10.1038/embor. 2008.238.
32. Nathan JA, Spinnenhirn V, Schmidtke G, Basler M, Groettrup M, Goldberg AL. 2013. Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. Cell 152:1184-1194. doi: 10.1016/ j.cell.2013.01.037.
33. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, van der Heijden JW, Ylstra B, Peters GJ, Kaspers GL, Dijkmans BA, Scheper RJ, Jansen G. 2008. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112:2489-2499. doi: 10.1182/blood-2007-08-104950.
34. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun J-A, Outzen H, Øvervatn A, Bjørkøy G, Johansen T. 2007. p62/ SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. The Journal of Biological Chemistry 282:24131-24145. doi: 10.1074/jbc.M702824200.
35. Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, Lorens JB, Micklem DR, Ruurs P, Sylvain C, Lu Y, Shenk KD, Bennett MK. 2009. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 114:3439-3447. doi: 10.1182/blood-2009-05-223677.
36. Radhakrishnan SK, Lee CS, Young P, Beskow A, Chan JY, Deshaies RJ. 2010. Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Molecular Cell 38:17-28. doi: 10.1016/j.molcel.2010.02.029.
37. Rousseau E, Kojima R, Hoffner G, Djian P, Bertolotti A. 2009. Misfolding of proteins with a polyglutamine expansion is facilitated by proteasomal chaperones. The Journal of Biological Chemistry 284:1917-1929. doi: 10. 1074/jbc.M806256200.
38. Röllig C, Knop S, Bornhäuser M. 2014. Multiple myeloma. Lancet 385:2197-2208. doi: 10.1016/S0140-6736(14) 60493-1.
39. Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, Cirstea D, Rodig S, Eda H, Scullen T, Canavese M, Bradner J, Anderson KC, Jones SS, Raje N. 2012. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 119:2579-2589. doi: 10.1182/blood-2011-10-387365.
40. Sarkar S. 2013. Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers. Biochemical Society Transactions 41:1103-1130. doi: 10.1042/BST20130134.
41. Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC. 2007. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. The Journal of Biological Chemistry 282:5641-5652. doi: 10.1074/jbc.M609532200.
42. Schmidt M, Finley D. 2014. Regulation of proteasome activity in health and disease. Biochimica et Biophysica Acta 1843:13-25. doi: 10.1016/j.bbamcr.2013.08.012.
43. Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image analysis. Nature Methods 9:671-675. doi: 10.1038/nmeth.2089.
44. SchwickartM, Huang X, Lill JR, Liu J, Ferrando R, French DM, Maecker H, O'Rourke K, Bazan F, Eastham-Anderson J, Yue P, Dornan D, Huang DC, Dixit VM. 2010. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 463:103-107. doi: 10.1038/nature08646.
45. Shah JJ, Orlowski RZ. 2009. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23:1964-1979. doi: 10.1038/leu.2009.173.
46. Steffen J, Seeger M, Koch A, Krüger E. 2010. Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. Molecular Cell 40:147-158. doi: 10.1016/j.molcel.2010.09.012.
47. Suraweera A, Münch C, Hanssum A, Bertolotti A. 2012. Failure of amino acid homeostasis causes cell death following proteasome inhibition. Molecular Cell 48:242-253. doi: 10.1016/j.molcel.2012.08.003.
48. Suzuki R, Hideshima T, Mimura N, Minami J, Ohguchi H, Kikuchi S, Yoshida Y, Gorgun G, Cirstea D, Cottini F, Jakubikova J, Tai YT, Chauhan D, Richardson PG, Munshi NC, Utsugi T, Anderson KC. 2015. Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma. Leukemia 29:510-514. doi: 10.1038/leu.2014.300.
49. Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, Rangwala R, Piao S, Chang YC, Scott EC, Paul TM, Nichols CW, Porter DL, Kaplan J, Mallon G, Bradner JE, Amaravadi RK. 2014. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy 10:1380-1390. doi: 10.4161/auto.29264.
50. Wagner SA, Beli P, Weinert BT, Nielsen ML, Cox J, Mann M, Choudhary C. 2011. A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles. Molecular & Cellular Proteomics 10:M111.013284. doi: 10.1074/mcp.M111.013284.
51. Wolf DH, Stolz A. 2012. The Cdc48 machine in endoplasmic reticulum associated protein degradation. Biochimica et Biophysica Acta 1823:117-124. doi: 10.1016/j.bbamcr.2011.09.002.
52. Zhu YX, Tiedemann R, Shi CX, Yin H, Schmidt JE, Bruins LA, Keats JJ, Braggio E, Sereduk C, Mousses S, Stewart AK. 2011. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood 117:3847-3857. doi: 10.1182/blood-2010-08-304022.